The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies
Open accessAbstract
Pseudomonas aeruginosa (P. aeruginosa) is a common pathogen isolated from patients with nosocomial infections. Due to its intrinsic and acquired antimicrobial resistance, limited classes of antibiotics can be used for the treatment of infection with P. aeruginosa. Of these, the carbapenems are very important; however, the occurrence of carbapenem-resistant strains is gradually increasing over time. Deficiency of the outer membrane protein OprD confers P. aeruginosa a basal level of resistance to carbapenems, especially to imipenem. Functional studies have revealed that loops 2 and 3 in the OprD protein contain the entrance and/or binding sites for imipenem. Therefore, any mutation in loop 2 and/or loop 3 that causes conformational changes could result in carbapenem resistance. OprD is also a common channel for some amino acids and peptides, and competition with carbapenems through the channel may also occur. Furthermore, OprD is a highly regulated protein at transcriptional and post-transcriptional levels by some metals, small bioactive molecules, amino acids, and efflux pump regulators. Because of its hypermutability and highly regulated properties, OprD is thought to be the most prevalent mechanism for carbapenem resistance in P. aeruginosa. Developing new strategies to combat infection with carbapenem-resistant P. aeruginosa lacking OprD is an ongoing challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations of specific porins OprD involving conformational features cause carbapenem resistance, a serious challenge for medical treatment practices.234”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [234]
In the citing paper
“Mutations of OprD in P. aeruginosa confers resistance to carbapenems234 and mutations of DNA gyrase (GyrA) causes resistance to quinolone antibiotics.257”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [234]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
High Frequency of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Lung Infection
Oliver, A., Cantón, R., Campo, P., Baquero, F., & Blázquez, J. (2000) · Science · doi:10.1126/science.288.5469.1251 · Cited by 1,465
Comparative Review of the Carbapenems
Zhanel, G. G., Wiebe, R., Dilay, L., Thomson, K., Rubinstein, E., Hoban, D. J., Noreddin, A. M., & Karlowsky, J. A. (2007) · Drugs · doi:10.2165/00003495-200767070-00006 · Cited by 652
Ko¨hler, T., Michéa‐Hamzehpour, M., Henze, U., Gotoh, N., Kocjancic Curty, L., & Pechère, J. (1997) · Molecular Microbiology · doi:10.1046/j.1365-2958.1997.2281594.x · Cited by 549
Quale, J., Bratu, S., Gupta, J., & Landman, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1633-1641.2006 · Cited by 409
Perron, K., Caille, O., Rossier, C., van Delden, C., Dumas, J.-L., & Köhler, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312080200 · Cited by 358
Köhler, T., Epp, S. F., Curty, L. K., & Pechère, J.-C. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.20.6300-6305.1999 · Cited by 302
Trias, J., & Nikaido, H. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.1.52 · Cited by 291
Emergence of Resistance to Imipenem During Therapy for Pseudomonas aeruginosa Infections
Quinn, J. P., Dudek, E. J., DiVincenzo, C. A., Lucks, D. A., & Lerner, S. A. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/154.2.289 · Cited by 276
Köhler, T., Michea-Hamzehpour, M., Epp, S. F., & Pechere, J.-C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.2.424 · Cited by 268
Ochs, M. M., McCusker, M. P., Bains, M., & Hancock, R. E. W. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1085 · Cited by 214
Trias, J., & Nikaido, H. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55452-1 · Cited by 210
Caille, O., Rossier, C., & Perron, K. (2007) · Journal of Bacteriology · doi:10.1128/jb.00095-07 · Cited by 174
Mushtaq, S., Ge, Y., & Livermore, D. M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.3086-3092.2004 · Cited by 164
Polyamine Effects on Antibiotic Susceptibility in Bacteria
Kwon, D.-H., & Lu, C. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01472-06 · Cited by 161
Incidence and bacteriology of burn infections at a military burn center
Keen, E. F., ROBINSON, B. J., Hospenthal, D. R., Aldous, W. K., Wolf, S. E., Chung, K. K., & Murray, C. K. (2010) · Burns · doi:10.1016/j.burns.2009.10.012 · Cited by 151
Lautenbach, E., Synnestvedt, M. B., Weiner, M. G., Bilker, W. B., Vo, L., Schein, J. R., & Kim, M. (2009) · Infection Control and Hospital Epidemiology · doi:10.1086/649021 · Cited by 140
In Vitro and In Vivo Activities of a New Cephalosporin, FR264205, against Pseudomonas aeruginosa
Takeda, S., Nakai, T., Wakai, Y., Ikeda, F., & Hatano, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00860-06 · Cited by 140
BARTH, A. L., & PITT, T. L. (1996) · Journal of Medical Microbiology · doi:10.1099/00222615-45-2-110 · Cited by 139
Hoban, D. J., Biedenbach, D. J., Mutnick, A. H., & Jones, R. N. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00540-0 · Cited by 136
Thomas, S. R., Ray, A., Hodson, M. E., & Pitt, T. L. (2000) · Thorax · doi:10.1136/thorax.55.9.795 · Cited by 131
Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates
Pirnay, J., Vos, D. D., Mossialos, D., Vanderkelen, A., Cornélis, P., & Zizi, M. (2002) · Environmental Microbiology · doi:10.1046/j.1462-2920.2002.00281.x · Cited by 122
Structural insight into OprD substrate specificity
Biswas, S., Mohammad, M. M., Patel, D. R., Movileanu, L., & van den Berg, B. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1304 · Cited by 102
Microbiologic aspects of predominant bacteria isolated from the burn patients in Korea
Song, W., Lee, K. M., Kang, H. J., Shin, D. H., & Kim, D. K. (2001) · Burns · doi:10.1016/s0305-4179(00)00086-3 · Cited by 98
Emergence of resistance to imipenem in Pseudomonas aeruginosa
Lynch, M. J., Drusano, G. L., & Mobley, H. L. T. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1892 · Cited by 94
Huang, H., & Hancock, R. E. W. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.11.3085-3090.1996 · Cited by 88
Conejo, M. C., Garcı́a, I., Martı́nez-Martı́nez, L., Picabea, L., & Pascual, Á. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2313-2315.2003 · Cited by 81
Hiroshi Yoneyama, C., & Nakae, T. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2385 · Cited by 80
Tanimoto, K., Tomita, H., Fujimoto, S., Okuzumi, K., & Ike, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00464-08 · Cited by 78
Farra, A., Islam, S., Strålfors, A., Sörberg, M., & Wretlind, B. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.016 · Cited by 73
Epp, S. F., Köhler, T., Plésiat, P., Michéa-Hamzehpour, M., Joachim Frey, A., & Pechère, J.-C. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1780-1787.2001 · Cited by 72
Membrane topology and site‐specific mutagenesis of Pseudomonas aeruginosa porin OprD
Huang, H., Jeanteur, D., Pattus, F., & Hancock, R. E. W. (1995) · Molecular Microbiology · doi:10.1111/j.1365-2958.1995.tb02319.x · Cited by 66
Hocquet, D., Plésiat, P., Dehecq, B., Mariotte, P., Talon, D. R., & Bertrand, X. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01646-09 · Cited by 61
Ochs, M. M., Lu, C., Hancock, R. E. W., & Abdelal, A. T. H. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.17.5426-5432.1999 · Cited by 61
Ochs, M. M., Bains, M., & Hancock, R. E. W. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1983-1985.2000 · Cited by 61
Sánchez-Gómez, S., Japelj, B., Jerala, R., Moriyón, I., Alonso, M. F., Leiva, J., Blondelle, S. E., Andrä, J., Brandenburg, K., Lohner, K., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00904-10 · Cited by 55
Koh, T. H., Khoo, C. T., Tan, T. T., Arshad, M. A. B. M., Ang, L., Lau, L. J., Hsu, L. Y., & Ooi, E. E. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01905-09 · Cited by 54
Fukuoka, T., Ohya, S., Narita, T., Katsuta, M., Iijima, M., Masuda, N., Yasuda, H., Trias, J., & Nikaido, H. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.322 · Cited by 51
Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review
Zilberberg, M. D., Chen, J., Mody, S. H., Ramsey, A. M., & Shorr, A. F. (2010) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-10-45 · Cited by 49
Lister, P., & Wolter, D. J. (2005) · Clinical Infectious Diseases · doi:10.1086/426190 · Cited by 47
Fukuoka, T., Masuda, N., Takenouchi, T., Sekine, N., Iijima, M., & Ohya, S. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.3.529 · Cited by 38
Protein D2 porin of the Pseudomonas aeruginosa outer membrane bears the protease activity
Yoshihara, E., Gotoh, N., Nishino, T., & Nakae, T. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00945-3 · Cited by 20
Lascols, C., Legrand, P., Mérens, A., Leclercq, R., Armand-Lefèvre, L., Drugeon, H., Kitzis, M.-D., Muller‐Serieys, C., Reverdy, M. E., Roussel‐Delvallez, M., et al. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-010-1117-6 · Cited by 16
Muramatsu, H., Horii, T., Morita, M., Hashimoto, H., Kanno, T., & Maekawa, M. (2003) · International Journal of Medical Microbiology · doi:10.1078/1438-4221-00256 · Cited by 11
Cited by
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Qin, S., Xiao, W., Zhou, C., Pu, Q., Deng, X., Lan, L., Liang, H., Song, X., & Wu, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01056-1 · Cited by 1,703
Peterson, E., & Kaur, P. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02928 · Cited by 1,006
New β-Lactam–β-Lactamase Inhibitor Combinations
Yahav, D., Giske, C. G., Grāmatniece, A., Abodakpi, H., Tam, V. H., & Leibovici, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-20 · Cited by 521
Haidar, G., Philips, N. J., Shields, R. K., Snyder, D., Cheng, S., Potoski, B. A., Doi, Y., Hao, B., Press, E. G., Cooper, V. S., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix182 · Cited by 277
Metadata
- Authors
- Li, H., Luo, Y.-F., Williams, B. J., Blackwell, T. S., & Xie, C.-M.
- Venue
- International Journal of Medical Microbiology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 302
- Issue
- 2
- Pages
- 63-68
- ISSN
- 1438-4221 (ISSN-L)
- OpenAlex
- W2044584162
- Cited by
- 266
- References
- 45
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.